Advertisement
MariMed Inc.

MariMed Inc. Fundamental Analysis

MRMD.CNCNQ
HealthcareDrug Manufacturers - Specialty & Generic
$0.10
$0.00(0.00%)
Canadian Market opens in 1h 6m
Advertisement

MariMed Inc. Fundamental Analysis

MariMed Inc. (MRMD.CN) shows weak financial fundamentals with a PE ratio of -2.11, profit margin of -7.82%, and ROE of -23.32%. The company generates $0.2B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position20.97%
PEG Ratio-0.12

Areas of Concern

ROE-23.32%
Operating Margin-0.84%
Current Ratio0.95
We analyze MRMD.CN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -30.5/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-30.5/100

We analyze MRMD.CN's fundamental strength across five key dimensions:

Efficiency Score

Weak

MRMD.CN struggles to generate sufficient returns from assets.

ROA > 10%
-6.29%

Valuation Score

Excellent

MRMD.CN trades at attractive valuation levels.

PE < 25
-2.11
PEG Ratio < 2
-0.12

Growth Score

Weak

MRMD.CN faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Weak

MRMD.CN carries high financial risk with limited liquidity.

Debt/Equity < 1
2.03
Current Ratio > 1
0.95

Profitability Score

Weak

MRMD.CN struggles to sustain strong margins.

ROE > 15%
-2331.70%
Net Margin ≥ 15%
-7.82%
Positive Free Cash Flow
Yes

Key Financial Metrics

Is MRMD.CN Expensive or Cheap?

P/E Ratio

MRMD.CN trades at -2.11 times earnings. This suggests potential undervaluation.

-2.11

PEG Ratio

When adjusting for growth, MRMD.CN's PEG of -0.12 indicates potential undervaluation.

-0.12

Price to Book

The market values MariMed Inc. at 0.55 times its book value. This may indicate undervaluation.

0.55

EV/EBITDA

Enterprise value stands at -6.06 times EBITDA. This is generally considered low.

-6.06

How Well Does MRMD.CN Make Money?

Net Profit Margin

For every $100 in sales, MariMed Inc. keeps $-7.82 as profit after all expenses.

-7.82%

Operating Margin

Core operations generate -0.84 in profit for every $100 in revenue, before interest and taxes.

-0.84%

ROE

Management delivers $-23.32 in profit for every $100 of shareholder equity.

-23.32%

ROA

MariMed Inc. generates $-6.29 in profit for every $100 in assets, demonstrating efficient asset deployment.

-6.29%

Following the Money - Real Cash Generation

Operating Cash Flow

MariMed Inc. generates limited operating cash flow of $7.32M, signaling weaker underlying cash strength.

$7.32M

Free Cash Flow

MariMed Inc. produces free cash flow of $6.04M, offering steady but limited capital for shareholder returns and expansion.

$6.04M

FCF Per Share

Each share generates $0.02 in free cash annually.

$0.02

FCF Yield

MRMD.CN converts 22.46% of its market value into free cash.

22.46%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-2.11

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.12

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.55

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.17

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

2.03

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.95

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.23

vs 25 benchmark

ROA

Return on assets percentage

-0.06

vs 25 benchmark

ROCE

Return on capital employed

-0.01

vs 25 benchmark

How MRMD.CN Stacks Against Its Sector Peers

MetricMRMD.CN ValueSector AveragePerformance
P/E Ratio-2.1133.74 Better (Cheaper)
ROE-23.32%404.00% Weak
Net Margin-7.82%-40219.00% (disorted) Weak
Debt/Equity2.030.81 Weak (High Leverage)
Current Ratio0.955.53 Weak Liquidity
ROA-6.29%-281.00% (disorted) Weak

MRMD.CN outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews MariMed Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ